Bristol-Myers Squibb Company
IMMUNOMODULATORS
Last updated:
Abstract:
In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.
Status:
Application
Type:
Utility
Filling date:
21 May 2020
Issue date:
11 Aug 2022